Enter multiple symbols separated by commas

Biotech and Pharmaceuticals


  • Kite Pharma CEO: Targeting cancer cells Wednesday, 24 Jun 2015 | 7:52 AM ET
    Kite Pharma CEO: Targeting cancer cells

    Arie Belldegrun, Kite Pharma CEO, discusses the future of immunotherapy and its collaboration to develop cancer T-cell therapies.

  • Inside Kite Pharma's 100% run Wednesday, 24 Jun 2015 | 7:51 AM ET
    Inside Kite Pharma's 100% run

    CNBC's Meg Tirrell takes a look at what's driving shares of Kite Pharma higher, as the biotech company announces it is joining forces with Bluebird to collaborate on cancer T-cell therapies.

  • Two big problems with generic-drug substitution Tuesday, 23 Jun 2015 | 3:54 PM ET
    Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • FDA approves new Medtronic's heart valve device Tuesday, 23 Jun 2015 | 3:29 PM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    The CEO of Medtronic talks new FDA approval and how to improve the health-care system.

  • Genetic based testing, growth area for us: DGX CEO Tuesday, 23 Jun 2015 | 1:15 PM ET
    Genetic based testing, growth area for us: DGX CEO

    Steve Rusckowski, Quest Diagnostics CEO, sits down with CNBC's Meg Tirrell for an exclusive interview.

  • Great time for Boston Scientific: CEO Tuesday, 23 Jun 2015 | 12:32 PM ET
    Great time for Boston Scientific: CEO

    CNBC's Meg Tirrell sits down with Michael Mahoney, Boston Scientific CEO, for an exclusive interview.

  • Excited about new product: Medtronic CEO Tuesday, 23 Jun 2015 | 11:39 AM ET
    Excited about new product: Medtronic CEO

    CNBC's Meg Tirrell sits down with Omar Ishrak, Medtronic CEO, for an exclusive interview to discuss the company's product pipeline and business strategy.

  • Charts: Biotech bull market intact, buy this ETF Monday, 22 Jun 2015 | 9:18 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Chart analyst John Kosar explains why biotech stocks have further to run, despite recent weakness.

  • Business of bacteria Friday, 19 Jun 2015 | 3:46 PM ET
    Business of bacteria

    Johnson & Johnson has established a microbiome institute to focus on developing treatments aimed at restoring the balance of micro-organisms. Details, with CNBC's Meg Tirrell.

  • Biotech bargain bin Friday, 19 Jun 2015 | 3:44 PM ET
    Biotech bargain bin

    CNBC's Morgan Brennan finds bargains in the outperforming biotech sector.

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • Biotechs about to break out: Pro Friday, 19 Jun 2015 | 1:41 PM ET
    Biotechs about to break out: Pro

    Michael Yee, RBC Capital Markets, biotech analyst, discusses growth to come in the biotech sector and forecasts if the all-time highs will continue. Also, which stocks to own in the space.

  • Microbiome studies changing human health Friday, 19 Jun 2015 | 8:33 AM ET
    Microbiome changing human health

    CNBC's Meg Tirrell explains what the microbiome is and why it's medicines new frontier.

  • Medicine's next frontier: The microbiome Friday, 19 Jun 2015 | 8:30 AM ET
    Bacteria illustration

    Fecal microbiota transplantation. It's exactly what it sounds like. And for patients such as Natalie Gurvich, it can seem like a miracle cure.

  • Biotech breakout to last? Thursday, 18 Jun 2015 | 3:25 PM ET
    Biotech breakout to last?

    Where the biotech sector is headed, with Rich Ross of Evercore ISI.

  • Botox-maker gets business facelift Wednesday, 17 Jun 2015 | 8:41 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Botox-maker Allergan Plc said it would buy Kythera Biopharmaceuticals Inc in a deal to expand its line of cosmetic treatments.

  • $180 million discovery from the placenta Wednesday, 17 Jun 2015 | 6:50 AM ET
    $180 million discovery from the placenta

    Biotech MiMedx sells amniotic membrane tissue that is used to help wounds heal 2-3 times faster than standard care. MiMedx CEO Pete Petit, discusses the effective tissue developed from the placenta.

  • Your drug prices too high? Here's who many blame Tuesday, 16 Jun 2015 | 3:00 AM ET

    Americans place controlling drug costs at the top of their health-related concerns.

  • UTHR CEO: Future of biotech Monday, 15 Jun 2015 | 4:25 PM ET
    UTHR CEO: Future of biotech

    CNBC's Meg Tirrell speaks to Martine Rothblatt, United Therapeutics CEO about the future of transplants and near-term RNA techniques.

  • What CVS-Target deal means for you Monday, 15 Jun 2015 | 1:55 PM ET
    A pedestrian passes a CVS store in New York

    CVS is buying Target's pharmacy business, but the deal shouldn't raise antitrust concerns or prices, NBC News reports.

Contact Biotech and Pharma


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.


  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.